Jacobio Pharmaceuticals Announces Publication of SHP2 Inhibitor Sitneprotafib Combination Therapy Data in Prestigious Journal

Reuters

May 09

Jacobio Pharmaceuticals Announces Publication of SHP2 Inhibitor Sitneprotafib Combination Therapy Data in Prestigious Journal

Jacobio Pharmaceuticals Group Co. Ltd. has announced a significant advancement in their clinical research with the publication of data on their SHP2 inhibitor, sitneprotafib (JAB-3312), in the prestigious journal, Clinical Cancer Research. The study showcases the potential of sitneprotafib in enhancing anti-tumor activity, particularly when combined with the KRAS G12C inhibitor glecirasib. The research highlights preclinical and clinical case studies targeting the RTK/RAS/MAPK pathway and PD-1 blockade therapies. This development aligns with Jacobio's commitment to pioneering innovative treatments in oncology, reinforcing their vision to become a global leader in drug research and development.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jacobio Pharmaceuticals Group Co. Ltd. published the original content used to generate this news brief on May 09, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2534197206"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2534197206\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2534197206?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-09 06:39","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2534197206","market":"nz","top_or_hot":-1,"title":"Jacobio Pharmaceuticals Announces Publication of SHP2 Inhibitor Sitneprotafib Combination Therapy Data in Prestigious Journal","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Jacobio Pharmaceuticals Announces Publication of SHP2 Inhibitor Sitneprotafib Combination Therapy Data in Prestigious Journal\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Jacobio Pharmaceuticals Group Co. Ltd. has announced a significant advancement in their clinical research with the publication of data on their SHP2 inhibitor, sitneprotafib (JAB-3312), in the prestigious journal, Clinical Cancer Research. The study showcases the potential of sitneprotafib in enhancing anti-tumor activity, particularly when combined with the KRAS G12C inhibitor glecirasib. The research highlights preclinical and clinical case studies targeting the RTK/RAS/MAPK pathway and PD-1 blockade therapies. This development aligns with Jacobio's commitment to pioneering innovative treatments in oncology, reinforcing their vision to become a global leader in drug research and development.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jacobio Pharmaceuticals Group Co. Ltd. published the original content used to generate this news brief on May 09, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Jacobio Pharmaceuticals Announces Publication of SHP2 Inhibitor Sitneprotafib Combination Therapy Data in Prestigious Journal</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nJacobio Pharmaceuticals Announces Publication of SHP2 Inhibitor Sitneprotafib Combination Therapy Data in Prestigious Journal\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-05-09 06:39</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Jacobio Pharmaceuticals Announces Publication of SHP2 Inhibitor Sitneprotafib Combination Therapy Data in Prestigious Journal\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Jacobio Pharmaceuticals Group Co. Ltd. has announced a significant advancement in their clinical research with the publication of data on their SHP2 inhibitor, sitneprotafib (JAB-3312), in the prestigious journal, Clinical Cancer Research. The study showcases the potential of sitneprotafib in enhancing anti-tumor activity, particularly when combined with the KRAS G12C inhibitor glecirasib. The research highlights preclinical and clinical case studies targeting the RTK/RAS/MAPK pathway and PD-1 blockade therapies. This development aligns with Jacobio's commitment to pioneering innovative treatments in oncology, reinforcing their vision to become a global leader in drug research and development.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jacobio Pharmaceuticals Group Co. Ltd. published the original content used to generate this news brief on May 09, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1574","symbol_name":"生物医药B类股","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250508:nNDL5Tj3Ph:1","article_id":"2534197206","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2534197206","pubTimestamp":1746743984,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Jacobio Pharmaceuticals Announces Publication of SHP2 Inhibitor Sitneprotafib Combination Therapy Data in Prestigious Journal. Jacobio Pharmaceuticals Group Co. Ltd. has announced a significant advancement in their clinical research with the publication of data on their SHP2 inhibitor, sitneprotafib , in the prestigious journal, Clinical Cancer Research. The study showcases the potential of sitneprotafib in enhancing anti-tumor activity, particularly when combined with the KRAS G12C inhibitor glecirasib. The research highlights preclinical and clinical case studies targeting the RTK/RAS/MAPK pathway and PD-1 blockade therapies. This development aligns with Jacobio's commitment to pioneering innovative treatments in oncology, reinforcing their vision to become a global leader in drug research and development.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-gene","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1574":"生物医药B类股","01167":"加科思-B","BK1161":"生物科技"},"translate_title":"Jacobio Pharmaceuticals宣布在著名期刊发表SHP2抑制剂Sitneprotafib联合治疗数据","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01167":0.9},"content_text":"Jacobio Pharmaceuticals Announces Publication of SHP2 Inhibitor Sitneprotafib Combination Therapy Data in Prestigious Journal\n    \n\n        Jacobio Pharmaceuticals Group Co. Ltd. has announced a significant advancement in their clinical research with the publication of data on their SHP2 inhibitor, sitneprotafib (JAB-3312), in the prestigious journal, Clinical Cancer Research. The study showcases the potential of sitneprotafib in enhancing anti-tumor activity, particularly when combined with the KRAS G12C inhibitor glecirasib. The research highlights preclinical and clinical case studies targeting the RTK/RAS/MAPK pathway and PD-1 blockade therapies. This development aligns with Jacobio's commitment to pioneering innovative treatments in oncology, reinforcing their vision to become a global leader in drug research and development.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jacobio Pharmaceuticals Group Co. Ltd. published the original content used to generate this news brief on May 09, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}